Vienna

• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell … Ended recruitment
  2023-509908-15-00 10 2020-01-20 Mantle Cell Lymphoma
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended recruitment
  2022-502478-18-00 4 2019-12-20 Acute Myeloid Leukemia (AML)
• A Study of Atezolizumab (Anti-PD-L1 Antibody) plus Bevacizumab versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellula … Ended recruitment
  2023-504303-86-00 5 2019-11-21 High-risk hepatocellular carcinoma (HCC)
• A randomized phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in pati … Ended recruitment
  2023-509463-24-01 4 2019-11-04 metastatic pancreatic cancer
• Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch … Ended recruitment
  2022-502354-14-00 5 2019-10-28 Completely resected Stage IIb/c melanoma
• Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno … Ended recruitment
  2023-503670-21-00 5 2019-08-28 Patients with newly diagnosed AML and intermediate- or adverse-risk ge
• Comparison of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumours Ended recruitment
  2023-507582-25-00 5 2019-08-02 Malignant Extracranial Germ Cell Tumours (MGCT)
• A Study of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Participants with Advanced Kidney Cancer. Ended recruitment
  2023-508264-29-00 5 2019-06-11 Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors
• A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specifi … Ended recruitment
  2024-511798-31-00 7 2019-05-31 KRAS p.G12C Mutant Advanced Solid Tumors
• A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea … Ended recruitment
  2023-510357-42-00 5 2019-05-22 hormone receptor (HR)-positive, HER2-negative, early breast cancer (EB
• An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertens … Ended recruitment
  2023-509305-68-00 5 2019-05-16 Pulmonary arterial hypertension (PAH)
• A prospective controlled trial to evaluate safety and efficacy of in vitro expanded recipient regulatory T cell therapy and tocilizumab toge … Ended recruitment
  2024-513459-34-00 9 2019-04-24 Kidney transplantation
• This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with alre … Ended recruitment
  2023-509349-11-00 5 2019-03-22 Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or
• A global study of midostaurin in combination with chemotherapy to evaluate safety, efficacy, and pharmacokinetics in newly diagnosed pediatr … Ended recruitment
  2023-509834-20-00 4 2019-03-13 untreated FLT3-mutated Acute Myeloid Leukemia
• A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease Ended recruitment
  2024-513884-20-00 5 2019-03-13 Fabry disease
• Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio … Ended recruitment
  2022-502832-37-00 5 2019-03-01 Acute myeloid leukemia
• A Study of Durvalumab Before and After Surgery for Patients with Operable Non-Small Cell Lung Cancer. Ended recruitment
  2023-509576-42-00 5 2019-02-21 Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB
• An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended recruitment
  2023-507906-15-00 5 2019-01-30 Relapsing multiple sclerosis (RMS)
• Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma … Ended recruitment
  2022-502937-24-00 5 2019-01-02 Atopic Dermatitis
• MK-3475 (SCH 9000475) as neoadjuvant and adjuvant therapy in Stage III-IVA resectable LA HNSCC (Locoregionally Advanced Head and Neck Squamo … Ended recruitment
  2022-500254-41-00 5 2018-12-13 Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamou
• An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Participants with … Ended recruitment
  2023-508463-71-00 5 2018-11-30 Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
• A Phase 3 trial of BCG with or without pembrolizumab for High Risk Non Muscle Invasive Bladder Cancer Ended recruitment
  2022-501817-29-00 5 2018-11-27 High Risk Non-muscle invasive bladder cancer
• A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Ended recruitment
  2023-506994-36-00 5 2018-10-11 Ulcerative Colitis

Showing 601–624 of 828 trials